Effect of a chronic disease management service for patients with diabetes on hospitalisation and acute care costs
Tshepo M. Rasekaba A , W. Kwang Lim A B and Anastasia F. Hutchinson A CA Northern Clinical Research Centre, Northern Health, 185 Cooper St, Epping, Vic. 3076, Australia. Email: tshepo.rasekaba@nh.org.au; kwang.lim@nh.org.au
B Department of Medicine, The University of Melbourne, Parkville, Vic. 3054, Australia.
C Corresponding author. Email: anastasia.hutchinson@nh.org.au
Australian Health Review 36(2) 205-212 https://doi.org/10.1071/AH10992
Submitted: 16 December 2010 Accepted: 20 June 2011 Published: 28 February 2012
Journal Compilation © AHHA 2012
Abstract
Objective. To evaluate the effect of a diabetes-management program for patients with type 2 diabetes and related comorbidities on acute healthcare utilisation and costs.
Methods. This was a retrospective administrative dataset analysis using data for patients enrolled from 2007 to 2008. Inpatient admissions for diabetes-related conditions were compared before, during and following enrolment. Costs per episode were estimated from Weighted Inlier Equivalent Separations (WIES) funding. A cost model was then developed based on admission rates per 100 patients.
Results. Data were retrieved for 357 patients; 49% males, mean age 62 years. The mean per-patient cost of the program was AU$524 (s.d. $213). The mean cost of an inpatient admission was $4357(95% CI 2743–5971) pre-enrolment and $4396 (95% CI 2888–5904) post-enrolment. Following program completion the annual costs (per 100 patients) for managing ‘diabetes with multiple complications’ and hypoglycaemia decreased from $10 181 to $1710 and $9947 to $7800. In contrast, the annual cost of cardiovascular disorders increased from $14 485 to $40 071 per 100 patients.
Conclusions. In the short-term diabetes-management programs for patients with comorbid vascular disease may reduce hospital utilisation for diabetes but not for cardiovascular disease. Longer-term follow-up is needed to determine whether intensive management of vascular complications can reduce costs.
What is known about the topic? Type 2 diabetes is now recognised as the fastest growing chronic disease in Australia and other western countries. In developed countries, diabetes is a leading cause of cardiovascular disease and renal failure, and, in the over 60 age group, is a leading cause of blindness and non-traumatic lower limb amputations. Glycated haemoglobin (HbA1c) is a measure of diabetes control, with set target levels for the prevention or delay of development of macrovascular and microvascular complications of diabetes. Epidemiological studies have demonstrated that a 1% reduction in HbA1c can lead to a 15–21% reduction in diabetes-related deaths and 33–41% reduction in microvascular complications over a 10-year period. Indicating that improvements in glycaemic control may have the potential to decrease acute healthcare costs associated with management of complications over the long term.
What does this paper add? There are limited data available on the short to medium term effect of disease-management programs for patients with already established complications on acute healthcare utilisation. This study evaluated the cost of providing the Northern Alliance Hospital Admission Risk Program for diabetes disease management and its effect on acute healthcare utilisation at Northern Health. In contrast, the overall inpatient costs for the management of diabetes and related conditions were high and did not decrease significantly following program completion. The major acute care cost drivers were surgical interventions for advanced peripheral vascular disease and the management of cardiovascular events.
What are the implications for practitioners? These findings demonstrate that in this population with a high prevalence of established cardiovascular and peripheral vascular complications that diabetes-management programs need to be equipped and resourced to manage these complications if potential savings in acute care costs are to be realised.
References
[1] Australia’s health 2008. Canberra: Australian Institute of Health and Welfare; 2008. Cat. No. AUS 99.[2] Dixon T. Costs of diabetes in Australia, 2000–01. Canberra: Australian Institute of Health and Welfare; 2005. Bulletin No. 26, AIHW Cat. No. AUS 59.
[3] Mathers C, Vos T, Stevenson S. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare; 1999. AIHW Cat. No. PHE 17.
[4] Barr ELM, Zimmet PZ, Polkinghorne KR, Atkins RC, Dunstan CW, Murray SG, et al. AusDiab 2005: the Australian diabetes, obesity and lifestyle study. Tracking the accelerating epidemic: its causes and outcomes. International Diabetes Institute; 2006.
[5] Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust 2008; 188 36–40.
[6] Georgiou A, Burns J, Harris M. GP claims for completing diabetes ‘cycle of care’. Aust Fam Physician 2004; 33 755–7.
[7] Improving care. Hospital Admission Risk Program: Public Report. Melbourne: Victorian Government Department of Human Services; 2006.
[8] Rasekaba TM. Chronic disease services patients in the Northern Alliance Hospital admission risk program-chronic disease management (HARP-CDM). 2009. MPH by Research Thesis, The University of Melbourne, Melbourne.
[9] Craver GA, Longo DR. Using instrumental variables regression to evaluate Medicaid disease management program effectiveness: an exploratory analysis. J Health Care Finance 2009; 36 15–30.
[10] Wheeler JRC. Can a disease self-management program reduce health care costs? The case of older women with heart disease. Med Care 2003; 41 706–15.
| Can a disease self-management program reduce health care costs? The case of older women with heart disease.Crossref | GoogleScholarGoogle Scholar |
[11] Lorig KL, Ritter P, Stewart AL, Sobel DS, Brown WB, Bandura A, Gonzalez VM, Laurent DD, Holman HR. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care 2001; 39 1217–23.
| Chronic disease self-management program: 2-year health status and health care utilization outcomes.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3Mnmt1alsw%3D%3D&md5=a2cf508e9b3fa1dbc8bed51b1333b9ceCAS |
[12] Villagra V. Strategies to control costs and quality: a focus on outcomes research for disease management. Med Care 2004; 42 24–30.
[13] Casemix Funding in Victoria. Melbourne: State Government of Victoria, Department of Health; 2009. Available at http://www.health.vic.gov.au/casemix/definitions [verified 7 December 2009].
[14] Australian Refined Diagnosis Related Groups (AR-DRGs). Australian Government, Department of Health and Ageing; 2009. Available at http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-casemix-ardrg1.htm [verified 8 December 2009].
[15] International Classification of Diseases (ICD), 10th Revision 2007 (ICD-10). Geneva: World Health Organization; 2007. Available at http://www.who.int/classifications/icd/en/ [verified 8 December 2009].
[16] Rasekaba TM, Graco M, Risteski C, Jasper A, Berlowitz DJ, Hawthorne G, Hutchinson A. Impact of a diabetes disease management program on diabetes control and patient quality of life. Popul Health Manag 2012; 15 12–9.
| Impact of a diabetes disease management program on diabetes control and patient quality of life.Crossref | GoogleScholarGoogle Scholar |
[17] Clarke P, Leal J, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in australia using administrative health-care data. Value Health 2008; 11 199–206.
| Estimating the cost of complications of diabetes in australia using administrative health-care data.Crossref | GoogleScholarGoogle Scholar |
[18] Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg 2010; 52 17S–22S.
| The costs of diabetic foot: the economic case for the limb salvage team.Crossref | GoogleScholarGoogle Scholar |
[19] Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, et al Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study group. BMJ 2000; 320 1373–8.
| Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study group.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3c3nvFyktg%3D%3D&md5=e80c509318fa5518c7c006d0da0e3c9eCAS |
[20] Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al Cost effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44 298–304.
| Cost effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3MXhsFCmsr8%3D&md5=94335fc23b95b60314c9a42ed722e494CAS |
[21] Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ. Improved survival of the diabetic foot: the role of a specialized foot clinic. Q J Med 1986; 60 763–71.
| 1:STN:280:DyaL2s%2FktFyqsQ%3D%3D&md5=9dc60a42dc7cedcdfb5df78b5f6c92eaCAS |
[22] Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 405–12.
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3cvisFWnsg%3D%3D&md5=5ce91c0d7d361912c08973d328ed112dCAS |
[23] ten Brinke R, Dekker N, de Groot M, Ikkersheim D. Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality. Prim Care Diabetes 2008; 2 45–9.
| Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality.Crossref | GoogleScholarGoogle Scholar |
[24] Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322 15–8.
| Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk).Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3M7mt1ejuw%3D%3D&md5=826d0f7a780d7a65e16ae9ca2619cd97CAS |
[25] Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008; 149 11–9.
[26] The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 977–86.
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.Crossref | GoogleScholarGoogle Scholar |
[27] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 1577–89.
| 10-year follow-up of intensive glucose control in type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXht1Wgt7nK&md5=37645b9fbc755fff943796de9d684872CAS |
[28] The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 2545–59.
| Effects of intensive glucose lowering in type 2 diabetes.Crossref | GoogleScholarGoogle Scholar |
[29] Casemix Calculator 2009–2010. Melbourne: Metropolitan and Aged Care Services, Department of Health (Victoria); 2009.
[30] Evans RG. Incomplete vertical integration: the distinctive structure of the healthcare industry. In: Van Der Gaag J, Pelmon M, editors. Health economics and health economics. Amsterdam: North Holland; 1981: 329–54.
[31] Eckermann S. Measuring health system efficiency and funding for net benefit maximisation: the health economics of quality of care. Working paper No. 2009/08. Centre for Clinical Change and Health Care Research, Finders University; 2009. Available at http://www.pc.gov.au/__data/assets/pdf_file/0011/90569/sub010-attachment1.pdf [verified 22 December 2011].
[32] Shwartz M. A primer: health care databases, diagnostic coding, severity adjustment systems and improved parameter estimation. Ann Oper Res 1996; 67 23–44.
| A primer: health care databases, diagnostic coding, severity adjustment systems and improved parameter estimation.Crossref | GoogleScholarGoogle Scholar |
